Nuvectis Pharma Inc expected to post a loss of 36 cents a share - Earnings Preview

Nuvectis Pharma

01/03/2024 13:03

* Nuvectis Pharma Inc  NVCT.OQ   NVCT.O  is expected to show
no
change in quarterly revenue when it reports  results on March 4
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Nuvectis Pharma Inc is
for a
loss of 36 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nuvectis
Pharma
Inc is $21.00​, above​ its last closing price of $9.87. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.35       -0.34      -0.37     Missed  -8.1
 Jun. 30 2023  -0.29       -0.29      -0.38     Missed  -30.3
 Mar. 31 2023  -0.44       -0.44      -0.27     Beat    38.8​
 Dec. 31 2022              -0.38                        
 ​​Sep.        -0.27       -0.27      -0.42     Missed  -55.6
 30 2022                                                
 Jun. 30 2022  -0.22       -0.23      -0.28     Missed  -20​
 Mar. 31 2022  -0.23       -0.23      -0.32     Missed  -39.1
 Dec. 31 2021  -0.85       -0.85      -0.48     Beat    43.5
 This summary was machine generated March 1 at 13:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)